cancer-primary-healthcare-2019-posters-abstracts

21 / 21

Page 45
Notes:
Volume 2 Journal of Molecular Cancer Cancer & Primary Healthcare 2019
May 20-21, 2019
Cancer Research & Oncology
Primary Healthcare and Medicare Summit May 20-21, 2019 | Rome, Italy
25 th Global Meet on
World Congress on
&
Overexpression of MAGE-A1 in lung cancer: a novel biomarker for prognosis, and a
possible target for immunotherapy
Seyed Alireza Javadinia
MUMS, Iran
Recently, broadadvances have beenmade indiagnostic and therapeuticmodalities against lung cancer.However,
little improvement in patient outcome has been achieved, especially for advanced, recurrent, and metastatic
lung cancers that have a significantly poor prognosis. We investigated melanoma-associated antigen A1
(MAGE-A1) expression in lung cancer tissues and its correlation with prognostic factors. In this cross-sectional
study, samples from 101 patients with lung cancer [including 80 NSCLCs (frequency of NSCLC subtypes, SCC
= 43, AC = 23, undifferentiated carcinoma = 9, and LCC = 5) and 21 SCLCs] were obtained between 2007 and
2014 and stained for MAGE-A1 by immunohistochemistry. Correlation with prognostic factors was assessed
by t-test and χ2 and Pearson tests. MAGE-1 IHC staining was positive in 56 (55.44%) patients with different
degrees of staining; PN1 in 13 (12.9%), PN2 in 24 (23.8%), and PN3 in 20 (19.8%) patients. Eighty nonsmall
cell and 21 small cell lung cancer specimens were stained for MAGE-A1. MAGE-A1 was detected more
commonly in adenocarcinomas and was expressed more frequently in male (P = 0.0001) and patients >60 years
(P = 0.005). MAGE-A1 expression was more frequent in the elderly, male patients, and those with advanced
stage and adenocarcinoma subtypes of lung cancer. Further investigations are needed to assess MAGE-A1
expression as a potential cancer biomarker. This retrospective study had all of the limitations associated with
this type of longitudinal cohort study. However, our study included a considerable number of patients, which
was done for the first time in our region. Also, we assessed the expression of MAGE-A1 as the products of
CT-X genes (instead of its presence, such as in studies that were conducted by PCR). This feature of our study
provided preliminary information for future investigation in term of new immune checkpoint therapy drugs.
J Mol Cancer, Volume 2